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Temperature-sensitive (ts) mutant viruses have been useful for the study of replication processes in many viral systems.
To determine how our panel of MHV-JHM-derived RNA2 ts mutants (Robb et al., 1979) is genetically related to other panels
of MHV RNA2 ts mutants, we tested our mutants for complementation with representatives from two different sets of
MHV-A59 ts mutants (Koolen et al., 1983; Schaad et al., 1990). These three ts mutant panels together comprise eight
genetically distinct complementation groups. Considerable genetic similarity was observed among the three mutant panels.
Only three complementation classes are unique to their particular mutant panel, and genetically equivalent mutants were not
observed within the other two mutant panels. There are two overlapping complementation groups between the mutant sets
derived from MHV-A59 and four overlapping complementation classes between the MHV-JHM panel and the MHV-A59
panels. Two complementation groups had representative mutants in all three mutant panels. One of these latter comple-
mentation classes demonstrated nonreciprocal complementation patterns consistent with intragenic complementation.
© 1998 Academic Press
INTRODUCTION
The MHV genome is a single, positive-stranded RNA
molecule over 31 kb in length (Lai and Stohlman, 1978;
Pachuk et al., 1989; Lee et al., 1991). The genomic RNA
is infectious (Lomniczi, 1977; Schochetman et al.,
1977) and is directly translated into a large polypeptide
which encodes polymerase and protease functions
(Bredenbeek et al., 1990 Lee et al., 1991). Replication
proceeds via synthesis of a negative-stranded com-
plement to the genomic RNA and transcription of a 39
coterminal nested set of viral mRNAs. The viral mRNAs
also share a common leader sequence 72–77 nucle-
otides in length, fused to their 59 ends (Lai et al., 1983,
1984; Spaan et al., 1983).
The precise molecular mechanism of viral RNA rep-
lication and transcription for mouse hepatitis virus
(MHV), a prototypic coronavirus, remains elusive. A
model featuring leader-primed transcription off a
genomic-length negative complement has been pos-
tulated to explain viral replication (Baric et al., 1983),
but this hypothesis remains controversial. Sub-
genomic negative-sense viral RNAs are also gener-
ated during infection and may function as replicons for
further mRNA synthesis (Sethna et al., 1989; Sawicki
and Sawicki, 1990; Schaad and Baric, 1994). The spe-
cific functions of various gene 1 products, with the
exception of the protease and zinc finger domains,
have not yet been addressed experimentally.
Gene 1 contains two reading frames, ORF1a and
ORF1b, that partially overlap for 75 nucleotides and
together are over 21 kb in length, comprising two-
thirds of the entire MHV genome (Lee et al., 1991;
Pachuk et al., 1989; Bonilla et al., 1994). The overlap-
ping region between the two open reading frames
contains a pseudoknot structure (Brierley et al., 1989;
Bredenbeek et al., 1990) that promotes ribosomal
frameshifting during translation. The predicted primary
translation product of gene 1 is approximately 800 kDa
(Lee et al., 1991). The polyprotein is proteolytically
cleaved into an unknown number of nonstructural pro-
teins that likely function in RNA synthesis.
Sequence analysis shows that ORF1a contains three
predicted protease domains: two amino-terminal papain-
like protease domains and a picornavirus 3C-like pro-
tease domain at the carboxyl-terminal end (Gorbalenya
et al., 1989; Lee et al., 1991). The first papain-like pro-
tease domain has been demonstrated to be active in
both in vitro and in vivo processing of the ORF1a-en-
coded polypeptides (Baker et al., 1989, 1993; Denison
and Perlman, 1986; Denison et al., 1991, 1992), and spe-
cific cleavage sites and protein products of the amino-
terminal 5 kb of gene 1 have been determined (Baker et
al., 1993; Denison and Perlman, 1986; Denison et al.,
1995; Hughes et al., 1995; Weiss et al., 1994). The 3C-like
protease is also functional, and many potential cleavage
recognition sites have been identified within gene 1
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(Baker et al., 1993; Denison and Perlman, 1986; Denison
et al., 1991, 1992).
Sequence comparisons of ORF1b with other RNA poly-
merase motifs show that it contains domains homolo-
gous to other viral RNA-dependent RNA polymerases
and helicases as well as metal ion finger-like domains,
functions all associated with RNA replication and tran-
scription (Gorbalenya et al., 1989; Bonilla et al., 1994;
Bredenbeek et al., 1990; Lee et al., 1991). ORF1b encodes
multiple potential 3C-like protease cleavage sites (Deni-
son et al., 1991; Weiss et al., 1994). Although it has been
demonstrated that the ORF1b-encoded portion of the
gene 1 polyprotein is processed into smaller precursors
(Denison et al., 1991), the exact processing of ORF1b
polypeptides, and their specific functions in RNA repli-
cation and transcription have yet to be determined.
Temperature-sensitive (ts) viral mutants have been
used to elucidate many different viral replication pro-
cesses and remain an important tool for investigating
viral replication. Over 15 years ago, two panels of ts
mutants of MHV-JHM were isolated (Haspel et al., 1978;
Robb et al., 1979). All of these mutants fail to grow at the
nonpermissive temperature (40°C), and in a subset of
mutants, RNA expression is defective if not completely
abolished. This subset of mutants was designated
‘‘RNA2’’ since all these mutants failed to direct synthesis
of genomic and/or subgenomic RNA at the nonpermis-
sive temperature (Robb et al., 1979; Leibowitz et al.,
1982). The MHV-JHM RNA2 mutants fall into six different
genetic complementation groups (Leibowitz et al., 1982).
Several groups have generated other panels of ts mu-
tants with MHV-A59 and MHV-3 (Koolen et al., 1983;
Schaad et al., 1990; Martin et al., 1988). These ts mutant
sets also show distinct genetic complementation, at
least within their own individual panels. Again, RNA2
mutants are found in each of these panels. The failure of
these mutant viruses to direct viral RNA synthesis at the
restrictive temperature suggests that mutations lie within
gene 1. The gene 1 mutations carried within one MHV-
A59 ts mutant panel have been ordered by recombina-
tion frequency analysis (Baric et al., 1990); additionally,
some individual mutants have been tentatively mapped
even more precisely (Fu and Baric, 1994). Although the
genetics and biochemistry of each set of mutants have
been investigated, no one has attempted to show how
these different ts mutant panels are related to each
other, thus limiting their usefulness. Genetic reconcilia-
tion of different mutant collections should enhance future
research and collaborations within the coronavirus field
in general, especially investigations of MHV gene 1
structure and function.
To determine the genetic relationships among the two
MHV-A59 mutant panels and the MHV-JHM mutants, we
have performed complementation assays utilizing these
three different ts mutant sets. The following experiments
show that MHV-JHM and MHV-A59 RNA2 mutants can
be genetically grouped and that certain complementa-
tion classes are common to all panels, while other
classes are unique.
RESULTS
Complementation analysis of MHV-A59 mutants
Complementation, or lack of complementation, of an
individual MHV-JHM ts mutant by another mutant in both
panels of MHV-A59 mutants was generally consistent
and reproducible. Table 1 shows the indices determined
from complementation tests of the Koolen et al. panel of
MHV-A59 mutants ts88, ts145, ts261, and ts329, with
members of MHV-JHM complementation classes A
through F. The MHV-A59 mutant ts88 falls into the MHV-
JHM B complementation class; MHV-A59 ts88 comple-
ments all other MHV-JHM mutants except MHV-JHM
tsB105. In contrast, MHV-A59 ts261 fails to complement
MHV-JHM tsA204 while complementing all other MHV-
JHM mutants. These results indicate that MHV-A59 ts261
is genetically equivalent to the MHV-JHM complementa-
tion class A. In contrast, MHV-A59 mutants ts145 and 329
complement all MHV-JHM complementation groups. Al-
though the complementation index of MHV-A59 ts145
with MHV-JHM tsA204 was relatively low in the experi-
ment shown (3.8), and falls into a range defined as
indeterminate, higher values obtained in other experi-
ments were indicative of complementation between
these two viruses. At first, based on visual observations,
MHV-A59 ts329 was believed to fall into the MHV-JHM
complementation class C. Cells dually infected with
MHV-A59 ts329 and MHV-JHM tsC106 rarely if ever form
syncytia at the nonpermissive temperature. However,
based on repeated experiments and continued positive
complementation indices, we are convinced MHV-A59
ts329 truly does complement MHV-JHM tsC106.
The Schaad et al. panel of MHV-A59 mutants also
yielded interesting results (Table 2). These mutants form
five distinct complementation classes with respect to
each other, and these classes have been tentatively
TABLE 1
Complementation of Koolen et al. MHV-A59 Mutantsa
Mutant
JHM
tsA204
JHM
tsB105
JHM
tsC106
JHM
tsD264
JHM
tsE248
JHM
tsF203
ts88 183 0.4 106 21.2 7.8 70
ts145 3.8 16 15.9 21.8/78b 7.3 24
ts261 0.2 71.3 16.2 129 121 5.3
ts329 104 113 80.5 18 18.2 11.2
a Each row represents the results from a single representative
complementation test, with the exception of the complementation in-
dices with tsF203, which were determined in a separate experiment as
described in the text.
b Double infection with MHV-A59 ts145 and MHV-JHM tsD129.
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ordered along gene 1 by recombination frequency anal-
ysis (Schaad et al., 1990; Baric et al., 1990). Additionally,
two of these MHV-A59 mutants, tsNC3 and tsLA18, and
revertant progeny of both viruses, have been partially
sequenced and putative mutations identified which may
mediate the ts phenotype (Fu and Baric, 1994). Comple-
mentation of MHV-JHM tsF203 was consistently difficult
and will be fully addressed later. Complementation anal-
ysis of the Schaad et al. panel of MHV-A59 mutants with
the MHV-JHM mutants (complementation groups A–E)
yielded two clear matches. MHV-A59 tsLA3 falls into the
MHV-JHM complementation group B (Table 2). The MHV-
JHM complementation class B is one of two complemen-
tation groups represented in all three panels. The MHV-
A59 mutant ts88 from the Koolen et al. panel and MHV-
A59 tsLA3 also fail to complement each other (CI 5 1.4).
Thus, MHV-A59 tsLA3 and ts88 and MHV-JHM tsB105 are
genetically equivalent and belong to the same comple-
mentation group. The Schaad et al. panel mutant, MHV-
A59 tsNC3, fails to complement MHV-JHM tsE248; there-
fore, it is equivalent to the MHV-JHM complementation
group E.
MHV-A59 tsLA18, the Schaad et al. panel group E
representative, clearly fails to complement the Koolen et
al. panel mutant, MHV-A59 ts145. All experiments clearly
indicated that MHV-A59 ts145 and MHV-A59 tsLA18 are
in the same complementation group. However, this mu-
tant also failed to complement MHV-JHM tsD264 and
MHV-JHM tsD129 (Table 3, see legend). This result was
completely unexpected. MHV-A59 ts145 efficiently com-
plements both MHV-JHM tsD264 and tsD129 (CI 5 78 in
dual infection of ts145 and tsD129, Table 1). This pattern
of nonreciprocal complementation may demonstrate the
presence of a double mutation within MHV-A59 tsLA18 or
intragenic complementation among the three mutants as
discussed below.
The other two Schaad et al. panel MHV-A59 mutants,
tsNC2 and tsLA10, complemented each MHV-JHM
complementation group (Table 2). MHV-A59 tsNC2
(Schaad et al. complementation group B) appears to be
genetically equivalent to the Koolen et al. panel MHV-A59
mutant ts329. Although the CI for the double infection of
MHV-A59 tsNC2 with MHV-JHM tsA204 is low (3.9), MHV-
A59 tsNC2 complemented MHV-JHM tsA201 (CI 5 5.4)
and MHV-A59 ts261 (CI 5 4). Both MHV-JHM tsA204 and
tsA201 are members of the MHV-JHM complementation
group A, and we have demonstrated above that the
Koolen et al. panel mutant, MHV-A59 ts261, falls into this
same complementation class. The mutant MHV-A59
tsLA10 forms a unique complementation class with re-
spect to both the MHV-JHM mutants and the Koolen et al.
MHV-A59 mutant panel.
Complementation of the JHM complementation group
F mutant, tsF203, with other mutants is difficult to dem-
onstrate. This difficulty is due to the high reversion fre-
quency of MHV-JHM tsF203 (1023) and the fact that
revertants appear early in the time course of infection
(Leibowitz, unpublished results). Complementation of
TABLE 2
Complementation of Schaad et al. MHV-A59 Mutantsa
Mutant
JHM
tsA204 JHM tsB105 JHM tsC106 JHM tsD264 JHM tsE248 JHM tsF203 A59 ts145 A59 ts329
tsLA3 120 0.5/1.4b 28.3 26.6 153 2.5 33.9 51
tsNC2 3.9/5.4c/4d 45.5 17.1 35.2 14.5 3 7.2 0.2
tsNC3 10.2 42.3 10.2 33.3 1.2 1.2 46.1 5.5
tsLA10 271.9 43.5 76.9 44.5 18.5 10.1 263 5.4
tsLA18 7.4 23.2 19.5 1.5 36 1.9 0.3 4
a Each row represents the results from a single representative complementation test, with the exception of the complementation indices with
tsF203, which were determined in a separate experiment as described in the text.
b Double infection with MHV-A59 tsLA3 and MHV-A59 ts88.
c Double infection with MHV-A59 tsNC2 and MHV-JHM tsA201.
d Double infection with MHV-A59 tsNC2 and MHV-A59 ts261.
TABLE 3
Complementation of Schaad et al. MHV-A59 tsLA18
Trial JHM tsA201/tsA204 JHM tsB105 JHM tsC106 JHM tsD264 JHM tsE248 A59 ts145 A59 ts329
1 7.4 23.2 19.5 1.5 36 0.3 4
2 7.1 13.2 1.9 0.96 3.6 0.03 17.2
3 1.2 855 4.4 1.7/2.5a 8.3 0.9 3.6
a Double infection with MHV-A59 tsLA18 and MHV-JHM tsD129.
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MHV-JHM tsF203 with other MHV-JHM mutants can be
only be demonstrated (CI . 5) if experiments are har-
vested at 12 h postinfection (Leibowitz et al., 1982). Con-
sequently, crosses of MHV-A59 mutants with MHV-JHM
tsF203 were carried out separately from the other
complementation assays. Even when infections are har-
vested at 12 h, complementation indices are often lower
than those values obtained in complementation tests
with other complementing MHV-JHM mutants (Leibowitz
et al., 1982; Leibowitz and Stalcup, unpublished results).
As shown in Tables 1 and 2, MHV-JHM tsF203 comple-
mented the Koolen et al. panel of MHV-A59 mutants and
MHV-A59 tsLA10, respectively, achieving complementa-
tion indices . 4. The complementation indices obtained
with the remainder of the Schaad et al. mutant panel are
less definitive. The complementation index obtained with
MHV-A59 tsNC2 is indeterminant. Positive complemen-
tation indices of MHV-JHM tsF203 were never obtained
in dual infections with the other Schaad et al. panel
MHV-A59 mutants (tsLA3, tsNC3, tsLA18). The comple-
mentation indices with MHV-JHM tsF203 were heavily
influenced by two factors: the high reversion rate of
MHV-JHM tsF203 alone and the presence of a high
number of revertants and recombinants in doubly in-
fected cultures.
Although complementation of MHV-JHM tsF203 with
MHV-A59 tsLA3, tsNC2, tsNC3, and tsLA18 cannot be
unequivocally demonstrated, we believe that MHV-JHM
tsF203 does not fall into any of the complementation
groups represented by these mutants, but represents a
unique complementation class. Our conclusion is based
on several observations. First, the complementation in-
dices do not yield an internally consistent classification
of MHV-JHM tsF203. This mutant reverts so readily to
wild-type (reversion frequency equals 4.6 3 1023) that it
is unlikely to carry multiple ts lesions that could result in
its failure to complement viruses representing several
distinct complementation groups. Furthermore, using
syncytia formation and CPE as indicators of viral repli-
cation, coinfection of cells with any of the mutants in
question and MHV-JHM tsF203 enhances replication rel-
ative to singly infected cultures. As shown in Fig. 1,
cultures doubly infected with MHV-A59 mutant and MHV-
JHM tsF203, and incubated 12 h at 40°C, consistently
FIG. 1. CPE observed in mouse 17 CL-1 cells infected with MHV-JHM tsF203 and a second complementing mutant virus. All cells were fixed at 12 h
postinfection and photographed as described under Materials and Methods. (A) Mock-infected cells. (B) Cells infected with MHV-JHM tsA204 and
tsF203 as a positive control for complementation. (C) Cells doubly infected with MHV-A59 tsLA3 and MHV-JHM tsF203. (D) Cells doubly infected with
MHV-A59 tsLA18 and MHV-JHM tsF203. (E) Cells infected with MHV-JHM tsF203 alone. (F) Cells singly infected with MHV-JHM tsA204. (G) Cells
infected with MHV-A59 tsLA3 alone. (H) Cells infected with MHV-A59 tsLA18 alone. Although not shown in this figure, in dual infections with MHV-JHM
tsF203 and either of the two MHV-A59 mutants, tsNC2 and tsNC3, extensive syncytia formation was also observed, to an extent similar to that seen
in these photomicrographs.
115COMPLEMENTATION ANALYSIS OF MHV MUTANTS
develop extensive cytopathic effects (syncytia formation,
Figs. 1A through 1E). One culture was doubly infected
with MHV-JHM tsA204 and MHV-JHM tsF203 as a posi-
tive control. Parallel cultures infected with a MHV-A59
mutant or with MHV-JHM tsA204 alone (Figs. 1F through
1J) never undergo cell fusion. Cells infected with MHV-
JHM tsF203 alone often develop a few scattered syncy-
tia, but never develop the extensive CPE observed in
cultures infected with both MHV-JHM tsF203 and one of
the MHV-A59 mutants or MHV-JHM tsA204. Cultures
doubly infected with MHV-JHM tsF203 and a MHV-A59
mutant that failed to complement MHV-JHM tsF203 (CI ,
4, Table 1) yielded amounts of CPE the same as or
greater than cultures doubly infected with MHV-JHM
tsF203 and MHV-JHM tsA204 (Fig. 1E) or MHV-A59 mu-
tant that did complement (e.g., MHV-A59 ts145 or tsLA10,
data not shown). As shown in Fig. 3D, similar results
were obtained with MHV-A59 tsLA18, a mutant that
yielded even lower complementation indices in dual in-
fections with MHV-JHM tsF203 (Table 2). Cultures doubly
infected with MHV-JHM tsF203 and MHV-A59 ts NC2 or
tsNC3 produced similarly high proportions of CPE (data
not shown). Previous complementation analysis with
MHV-JHM (Leibowitz et al., 1982), and results presented
here, indicate that for mutants defective in RNA synthe-
sis, the development of extensive CPE is usually a strong
indicator of complementation.
Finally, all of the MHV-A59 mutants that fail to comple-
ment MHV-JHM tsF203 can be classified into discrete
complementation groups, and the other members within
these complementation groups do complement MHV-
JHM tsF203. Therefore we conclude that MHV-JHM
tsF203 indeed represents a separate complementation
class (of which it is the sole member) apart from all of the
MHV-A59 ts mutants tested in this study.
The relationships of the three mutant collections to
each other, as deduced from the complementation
data, are summarized in the Venn diagram shown in
Fig. 2. Complementation analysis indicates that there
are at least eight genetically complementable, trans-
acting functions encoded by gene 1. All three MHV
mutant collections show considerable overlap in ge-
netic complementation. MHV-A59 tsLA10 represents
the only unique complementation class among the two
MHV-A59 panels. The MHV-JHM panel contains two
unique complementation groups represented by MHV-
JHM tsC106 and tsF203. There are two complementa-
tion groups which contain members from all three
panels of mutants. MHV-A59 ts145 and tsLA18, and
MHV-JHM tsD264, all bounded by yellow circles, likely
represent a single related complementation group
(see Discussion below), as does the complementation
group containing MHV-JHM tsB105 and MHV-A59 ts88
and tsLA3.
DISCUSSION
While several separate collections of temperature-
sensitive RNA2 mutants of MHV have been isolated and
studied, genetic relationships across these panels have
not been investigated. Although our work indicates that
there is considerable genetic overlap between the mu-
tants within the three panels, we have identified at least
eight putative RNA2 complementation groups in MHV.
These mutants presumably contain mutations within
gene 1 leading to defective RNA expression.
Gene 1, the polymerase gene of MHV, is 21,798 nucle-
otides in length and consists of two overlapping open
reading frames, ORF1a and ORF1b. It is translated into a
large polyprotein (800 kDa) that is proteolytically pro-
cessed into an unknown number of replication proteins
in vivo. ORF1a appears to encode at least five separate
gene products: p28, p65, p50, p240, and the 3C-like
protease, listed in order from 59 to 39. Polypeptide prod-
ucts of ORF1b have yet to be defined; however, four
ORF1b-specific products have been detected in cells
infected with equine arteritis virus (EAV), a related coro-
navirus superfamily virus (van Dinten et al., 1996). These
polypeptides are recognized by antibodies specific for
sequential regions of predicted amino acid sequence
between putative EAV nsp4 serine protease cleavage
sites, and the larger two polypeptides, p80 and p50,
contain the polymerase and helicase domains, respec-
tively. If the polyprotein encoded by ORF1b were cleaved
at putative 3C protease recognition sites, five cleavage
products of 108, 61, 66, 25, and 51 kDa would be ex-
pected (again in 59 to 39 order). ORF1b has been trans-
lated in vitro, and five polypeptides were isolated (Deni-
son et al., 1991). Antibodies directed against partial
ORF1b fusion proteins immunoprecipitate p90, p74, p53,
p44, and p32. The disparities in size between the pre-
dicted and observed polypeptides are being investi-
gated.
If ORF1a and ORF1b together encode 10 (at least)
distinct proteins, there should be, in theory, 10 comple-
mentation groups. The Schaad et al. MHV-A59 panel (5
distinct groups) account for half of the expected comple-
mentation groups. Together, the collection of MHV-JHM
ts mutants and the Koolen et al. panel of MHV-A59
mutants account for 3 more complementation groups.
Theoretically, there may be 2 additional undescribed
complementation classes that are not represented by
any mutants in this study.
Several results of this study were unexpected. As
observed previously (Leibowitz et al., 1982), syncytia for-
mation and CPE accompany complementation between
two individual mutants. However, cells dually infected
with MHV-JHM tsC106 and MHV-A59 ts329 yield comple-
mentation indices . 4, but rarely produce extensive CPE
and syncytia. It is possible, given the dosage of the
mutagen 5-fluorouracil used to generate both MHV-JHM
116 STALCUP, BARIC, AND LEIBOWITZ
tsC106 and MHV-A59 ts329, and the random positioning
of viable genetic substitutions throughout the genome in
the surviving viral mutant isolates, that there are addi-
tional mutations affecting genes downstream of gene 1
that might account for the lack of observable CPE and
syncytia in the face of active genetic complementation.
The most surprising finding concerned the genetic
relationships of MHV-A59 tsLA18, MHV-A59 ts145, and
MHV-JHM tsD264. MHV-A59 tsLA18 could not comple-
ment either of these mutants, whereas MHV-A59 ts145
complements both members of the MHV-JHM comple-
mentation group D (tsD264 and tsD129) very effectively.
One possible explanation for these data assumes the
causative mutations in MHV-JHM tsD264 and tsD129 and
MHV-A59 ts145 reside in two different polypeptides, re-
spectively. Further, MHV-A59 tsLA18 could harbor ts le-
sions in both of these putative polypeptides. However,
the putative mutation within MHV-A59 tsLA18 has been
localized using recombination frequency analysis to the
extreme 39 end of ORF1b (Baric et al., 1990). Revertants
of MHV-A59 tsLA18 have been sequenced and corre-
lated with a single substitution at nucleotide 20,455. If
tsLA18 were in fact a double mutant, recombination
frequency analysis would not have yielded a straightfor-
ward conclusion (e.g., MHV-A59 tsLA18 is downstream
of other gene 1 mutants in the Schaad et al. panel)
unless these two mutations were close together. In that
case, the two postulated mutations would have been
revealed upon sequencing of tsLA18 and its revertants.
Since this result was not obtained, it appears unlikely
FIG. 2. The genetic relationships between MHV temperature-sensitive mutants as determined by complementation analysis. Each panel of mutants
is represented as a set bounded by a circle (MHV-A59, Koolen et al. panel) or an oval (MHV-JHM panel; MHV-A59, Schaad et al. panel). Individual
members of each mutant panel are listed. Mutants which failed to complement each other and are thus in the same complementation group are
grouped together within the intersecting portions of the circle and the two ovals. Thus, MHV-A59 ts88, MHV-A59 tsLA3, and MHV-JHM tsB belong to
a single complementation group which is represented in each of the three panels of mutants and is contained in the region of the figure where the
three sets intersect. The complementation group containing MHV-JHM tsA and MHV-A59 ts88 is present in only two of the three panels and is thus
contained in the region of the figure where these two sets intersect. The exceptions to this representation are mutants MHV-JHM tsD, MHV-A59 ts145,
and MHV-A59 tsLA18. These three mutants, contained within the small yellow ovals, exhibit intracistronic complementation and represent a single
complementation group.
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that MHV-A59 tsLA18 is a double mutant. An alternative
explanation for the paradoxical complementation results
is intracistronic complementation.
Intracistronic complementation (also referred to as inter-
allelic complementation in the case of complementing mu-
tations of the same gene in diploid organisms) refers to
complementation by mutant polypeptide chains produced
by the same genetic locus and has been reviewed by Zabin
and Villarejo (1975). This differs from the more usual situa-
tion, in which mutations within the same polypeptide are
noncomplementary (Hayes, 1968). Hayes made some gen-
eralizations regarding this complementation: for interallelic
or intracistronic complementation to occur, synthesis of the
mutant protein must not be severely deranged, and the
activities of each of the separate complementing polypep-
tides should be qualitatively and quantitatively different
from those properties as observed in the wild-type protein.
Often intracistronic complementation is seen when the tar-
get of the mutation is an oligomeric protein. Escherichia coli
alkaline phosphatase is a well-studied model (Garen and
Garen, 1963; Schlesinger and Levinthal, 1963). Pairs of
different alkaline phosphatase mutants can complement in
vivo (Garen and Garen, 1963). Purified nonfunctional dimers
of alkaline phosphatase produced by differing mutants can
complement in vitro when sequentially denatured and re-
natured, allowing the mutant polypeptides to reassociate
into functional heterologous dimers (Schlesinger and
Levinthal, 1963). Mutations that affect the interacting do-
mains or the interface of subunits of the oligomeric protein
fail to complement other mutants that may intracistronically
complement each other.
The complementation relationships we observed for
MHV-A59 tsLA18, MHV-A59 ts145, and MHV-JHM tsD264
are precisely those expected for intracistronic comple-
mentation in a genetic locus encoding an oligomeric
protein. A protein has not been expressed or isolated
from the region of ORF1b where the MHV-A59 tsLA18
mutation has been mapped. Once polypeptides encoded
from this area of ORF1b are isolated, in vitro experiments
to define the nature of the mutations responsible for this
apparent intracistronic complementation can be at-
tempted.
The Schaad et al. panel complementation group E, as
determined by recombination frequency analysis (Baric
et al., 1990), is located at the extreme 39 end of ORF1b.
MHV-A59 tsLA18 is a member of this complementation
group, and as mentioned above, its putative mutation
has been mapped to nucleotide 20,455. Nucleotide
20,455 is downstream of the last putative 3C protease
cleavage site, so we believe that the mutations repre-
sented by the identified intracistronic complementation
group likely affect the carboxyl-terminal product of the
gene 1 polyprotein. The carboxyl-terminal end of ORF1b
is well conserved across coronavirus species (Lee et al.,
1991; Bredenbeek et al., 1990). However, its sequence
reveals no apparent protein motifs or obvious multimer-
ization domains. This is the first example of possible
intragenic complementation described in a coronavirus.
Sindbis ts RNA2 mutants have demonstrated that le-
sions in the same nonstructural protein can produce
different genetic complementation groups (Hahn et al.,
1989a,b), but to our knowledge the pattern of nonrecip-
rocal complementation we observed with the MHV-A59
tsLA18/ts145/MHV-JHM tsD group has not been previ-
ously described for mutants of RNA viruses with defects
in RNA synthesis.
The results of our complementation tests allow the
grouping of the three disparate panels of mutants. The
Schaad et al. panel of MHV-A59 mutants has been or-
dered by recombination frequency analysis along the
length of gene 1 (Baric et al., 1990). Thus the mutations
responsible for a ts phenotype in a complementation
group including one of the Schaad et al. mutants should
cluster in a discrete region of gene 1. Taken together,
these data allow directed sequencing strategies to rela-
tively limited regions, significant in an open reading
frame nearly 22 kb in length, and should aid further
sequencing and characterization of gene 1 mutants.
These data are already being applied to map mutants in
the MHV-JHM complementation group A (e.g., MHV-JHM
tsA204, MHV-A59 ts261). Work in progress suggests that
MHV-A59 ts261 is very close to MHV-A59 tsNC3, the
Schaad et al. group C mutant that maps to the overlap-
ping frameshift region between ORF1a and ORF1b.
MATERIALS AND METHODS
Cell lines and viruses
Mouse 17Cl-1 cells (Sturman and Takemoto, 1972) and
L2 cells (Rothfels et al., 1959) were grown in glass pre-
scription bottles in Dulbecco’s modified Eagle’s medium
(DME) containing 10% calf serum. All virus manipulations
were done in DME with a final serum concentration of 2%
(DME-2). Virus working stocks were grown in 17Cl-1 cells
(Bond et al., 1979; Robb and Bond, 1979); this line was
also used for all complementation assays. Mouse L2
cells were used for all viral plaque assays and plaque
purification of viral clones.
The isolation and phenotypic characterization of MHV-
JHM temperature-sensitive RNA2 mutants have been
described previously (Haspel et al., 1978; Robb et al.,
1979; Leibowitz et al., 1982). The representative viruses
used in this study were tsA201, tsA204, tsB105, tsC106,
tsD129, tsD264, tsE248, and tsF203. Standard nomencla-
ture of these MHV-JHM mutants includes a capital letter
before the isolate number to denote the MHV-JHM
complementation group to which the mutant belongs; the
number refers to the mutagen used and the individual
viral isolate (Leibowitz et al., 1982). For example, ‘‘tsC106’’
can be translated as temperature-sensitive mutant, be-
longing to complementation group C, mutagenized with
5-fluorouracil, viral mutant isolate No. 6.
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Two sets of RNA2, MHV-A59 temperature-sensitive
mutants were used in this study. One set, kindly provided
by Dr. Willy Spaan and referred to as the Koolen et al.
panel, contained the mutants ts88, ts145, ts261, and
ts329 (Koolen et al., 1983). Each of the mutants in the
Koolen et al. panel represents a distinct complementa-
tion group, and their numerical designations are histor-
ical and arbitrary. A fifth mutant, MHV-A59 ts342 (Koolen
et al., 1983), representing another distinct complementa-
tion group, proved unsuitable for further genetic analysis
due to its high reversion frequency (1023, Leibowitz,
unpublished results). A second set of MHV-A59 ts mu-
tants described by Schaad et al. (1990), designated the
Schaad et al. panel, was also employed. Viruses from the
Schaad et al. panel of MHV-A59 RNA2 mutants were
tsLA3, tsNC2, tsNC3, tsLA10, and tsLA18 and had been
previously assigned to complementation groups A
through E, respectively (Schaad et al., 1990). The letter
designations for these five complementation groups
were based on relative positioning of the mutants 59 to 39
within the body of gene 1 by recombination frequency
mapping (Baric et al., 1990). The Schaad et al. panel
complementation group A, for example, was not as-
sumed to be equivalent to the JHM complementation
group A.
Viruses from both MHV-A59 mutant panels were
plaque-purified at least twice. Virus stocks were pre-
pared at low multiplicity of infection under permissive
conditions (34.5°C).
Complementation analysis
Pairwise complementation assays were performed in
17Cl-1 cells 12 h after seeding 5 3 104 cells per well in
96-well plates (Corning Cell Wells No. 25860). Single
infections with each test virus were included to control
for reversion, and dual infections with known comple-
menting pairs of the MHV-JHM mutants were included as
positive controls. Inocula containing 1.5 3 105 PFU of
each virus (m.o.i. 5 3 PFU/cell for each virus) were
adsorbed onto cells for 1 h at room temperature. Inocula
volumes were equalized with DME-2. After adsorption,
inocula were aspirated and warm DME-2 was added to
infected wells. Infections were incubated at 40°C. At 16 h
postinfection (or 12 h postinfection for experiments using
MHV-JHM tsF203), plates were scored for cytopathic
effect (CPE) and frozen at 270°C. The thawed contents
of each well were mixed with 800 ml cold DME-2 (final
volume approximately 1 ml) and sonicated on ice 3 3
20 s. These viral stocks were titrated in serial 10-fold
dilutions on confluent L2 cells at both 34.5°C (permis-
sive) and 40°C (nonpermissive) as described previously
(Leibowitz et al., 1982).
Complementation indices (CI) were calculated using
the equation
CI 5
40@A 3 B#34.5 2
40@A 3 B#40
40@A#34.5 1
40@B#34.5
,
where 40[A 3 B]34.5 was the titer at permissive temper-
ature of a given dual infection in the assay and 40[A 3
B]40 was the titer at nonpermissive temperature of the
same dual infection. 40[A]34.5 and
40[B]34.5 were the titers
of each individual virus (single infection at nonpermis-
sive temperature, 16 h postinfection) assayed at permis-
sive temperature; this denominator controls for the intrin-
sic reversion frequency of each mutant tested.
CI values higher than four were considered positive for
complementation, CI values lower than two were con-
sidered negative. CI values between two and four were
considered indeterminate. All complementation test
were performed at least twice and usually three times.
Additional repetitions of the assay were needed to re-
solve the complementation assignment for some viruses.
Cell fixation and photography
The 17Cl-1 cells, 2 3 105 cells per well, were seeded
on chamber slides (Lab-Tech No. 177402) 12 h prior to
infection. Cells were infected with mutant viruses singly
or pairwise at a multiplicity of infection of 3 PFU per cell.
Viral adsorption proceeded for 1 h at room temperature.
Inocula were then aspirated, 0.4 ml warm DME-2 was
added, and cells were incubated at 40°C. Cells were
visually inspected for CPE at 12 h postinfection, washed
once with cold phosphate-buffered saline, and fixed with
1% glutaraldehyde in PBS.
Following fixation, slides were coverslipped with 10%
glycerol in PBS and sealed. Photographs were taken at
1003 magnification on an inverted phase microscope
(Nikon Diaphot).
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